| Literature DB >> 27425170 |
L Cuervo-Pardo1, M Barcena-Blanch2, C Radojicic3.
Abstract
The treatment of antihistamine and steroid resistant Chronic Idiopathic Urticaria (CIU) during pregnancy poses a challenge due to teratogenicity of immunosuppressants. Omalizumab is a recently FDA approved therapy for CIU and is classified as pregnancy category B. We present an initial series of subjects treated at a tertiary care center for antihistamine and steroid resistant CIU with omalizumab who became pregnant during therapy.Entities:
Keywords: Omalizumab; pregnancy; urticaria
Mesh：
Substances：
Year: 2016 PMID： 27425170
Source DB: PubMed Journal: Eur Ann Allergy Clin Immunol ISSN： 1764-1489